Corporate Presentation

corporate-presentation-thumb

Download January 2025 Presentation

Select Highlights

February 11, 2025

Oppenheimer Healthcare Life Sciences Conference

Access Webcast  »
January 15, 2025

J.P. Morgan Healthcare Conference

View Presentation  »
December 7, 2023

STAT6 Program Highlighted in Sanofi R&D Day

Access Webcast »

Latest Press Releases

May 7, 2025

Recludix Pharma Presents Preclinical Data on First-in-Class BTK SH2 Domain Inhibitor Demonstrating Powerful BTK Inhibition, Exceptional Selectivity, and Encouraging Efficacy in a Model of Chronic Spontaneous Urticaria

Read More »
February 10, 2025

Recludix Pharma to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Read More »
January 10, 2025

Recludix Pharma to Present at the Annual J.P. Morgan Healthcare Conference

Read More »
November 25, 2024

Recludix Pharma to Participate in Two Investor Conferences in December

Read More »
More Press Releases

Events and Presentations

February 11, 2025

Oppenheimer Healthcare Life Sciences Conference

Access Webcast  »
January 15, 2025

J.P. Morgan Healthcare Conference

View Presentation  »
December 7, 2023

STAT6 Program Highlighted in Sanofi R&D Day

Access Webcast »
More Events and Presentations

News Coverage Highlights

August 7, 2023

BioCentury: Recludix: targeting STATs via their SH2 domains

Read More »
July 20, 2023

BioWorld:  Recludix enters a potential $1.2B deal with Sanofi

Read More »
July 20, 2023

SCRIP: Sanofi Adds To Immunology Pipeline In Collaboration With Recludix  

Read More »
July 20, 2023

Fierce Biotech: Sanofi pays $125M to go after undruggable inflammatory target with Recludix’s preclinical program

Read More »
July 20, 2023

Endpoints News: Following Dupixent’s rise, Sanofi heads downstream in immunology for $125M small molecule pact with Recludix

Read More »
MENU